TIDMGEN
Company Announcement
-- At Genmab A/S' Annual General Meeting held today March 29, 2022, the
Annual Report for 2021 was approved
-- Discharge was given to the Board of Directors and the Executive
Management and the year's profit was carried forward
-- The 2021 Compensation Report was approved
-- One new member of the Board of Directors was elected, and five members of
the Board of Directors were re-elected
-- PricewaterhouseCoopers was re-elected as auditor of the Company
-- The proposal from the Board of Directors on the Board of Directors'
remuneration for 2022 was adopted
COPENHAGEN, Denmark; March 29, 2022 --
https://www.globenewswire.com/Tracker?data=li4Os-pzfW6SMgQM9GbDoDRdCcD_yn5d_vuPmYF3_5tyV7JS9NiS51SiZODipY7gJNkM4U8XvEZ-Ut_B_OCZ9A==
Genmab A/S (Nasdaq: GMAB) held its Annual General Meeting, today at
the Copenhagen Marriott Hotel, Copenhagen, Denmark. At the meeting,
Deirdre P. Connelly, Chair of the Board of Directors gave -- on
behalf of the Board of Directors -- a report on the Company's
activities during the past year. Chief Executive Officer Dr. Jan
van de Winkel presented the Company's plans for 2022, and Chief
Financial Officer Mr. Anthony Pagano presented the Annual Report
for 2021 endorsed by the auditors. The report was approved, and
discharge was given to the Board of Directors and the Executive
Management.
It was decided that the year's profit of DKK 3,008 million be
carried forward by transfer to retained earnings, as stated in the
Annual Report.
The 2021 Compensation Report was approved.
Ms. Elizabeth O'Farrell was elected to the Board of Directors
for a one-year period. Ms. Deirdre P. Connelly, Ms. Pernille
Erenbjerg, Mr. Rolf Hoffmann, Dr. Paolo Paoletti, and Dr. Anders
Gersel Pedersen were re-elected to the Board of Directors for a
one-year period.
The Board of Directors is hereafter comprised of:
Ms. Deirdre P. Connelly,
Ms. Pernille Erenbjerg
Mr. Rolf Hoffmann
Dr. Paolo Paoletti
Dr. Anders Gersel Pedersen
Ms. Elizabeth O'Farrell
Mr. Martin Schultz (Employee elected member)
Ms. Mijke Zachariasse (Employee elected member)
Mr. Takahiro Hamatani (Employee elected member)
PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab
was re-elected as the Company's auditor.
The General Meeting adopted the proposal from the Board of
Directors to adopt the Board of Directors' remuneration for
2022.
About Genmab
Genmab is an international biotechnology company with a core
purpose to improve the lives of people with cancer. For more than
20 years, Genmab's vision to transform cancer treatment has driven
its passionate, innovative and collaborative teams to invent
next-generation antibody technology platforms and leverage
translational research and data sciences, fueling multiple
differentiated cancer treatments that make an impact on people's
lives. To develop and deliver novel therapies to patients, Genmab
has formed 20+ strategic partnerships with biotechnology and
pharmaceutical companies. Genmab's proprietary pipeline includes
bispecific T-cell engagers, next-generation immune checkpoint
modulators, effector function enhanced antibodies and antibody-drug
conjugates.
Genmab is headquartered in Copenhagen, Denmark with locations in
Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo,
Japan. For more information, please visit Genmab.com
https://www.globenewswire.com/Tracker?data=li4Os-pzfW6SMgQM9GbDoJUj4t20nFeS9RidgLivCkIp9vHCtJihOW5PvrtRt0avyPsF5oSVNaJIlmAd4ftNhw==
and follow us on Twitter.com/Genmab
https://www.globenewswire.com/Tracker?data=YfPiwtVvlpRsoXhZNsMtOTs-hxMuJF3LF7vEILvqFwEm3m1EbxC64zoucNNzoxV5xcRsfNkzJKylu4bFl9tXab5wDyBC59SudOt6JWkJGNg=
.
Contact:
Marisol Peron, Senior Vice President, Global Investor Relations
& Communications
T: +1 609 524 0065; E: mmp@genmab.com
https://www.globenewswire.com/Tracker?data=3KAOyA95Tovia37A6QQVu-C4YhG_H8aPRX061BLQxL1UIhLxmZYHs9XbMiWsW-cqHsVr1UZZX2QBPlqe84gH3g==
For Investor Relations:
Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com
https://www.globenewswire.com/Tracker?data=BkZmS5ZNd4Mb0yDGInscleyy0hDyY3lIbwA9JU0AnYMFXZUidTIH73d1_m69_NAniCBixXX5D3UkYCagkNAiRA==
This Company Announcement contains forward looking statements.
The words "believe", "expect", "anticipate", "intend" and "plan"
and similar expressions identify forward looking statements. Actual
results or performance may differ materially from any future
results or performance expressed or implied by such statements. The
important factors that could cause our actual results or
performance to differ materially include, among others, risks
associated with pre-clinical and clinical development of products,
uncertainties related to the outcome and conduct of clinical trials
including unforeseen safety issues, uncertainties related to
product manufacturing, the lack of market acceptance of our
products, our inability to manage growth, the competitive
environment in relation to our business area and markets, our
inability to attract and retain suitably qualified personnel, the
unenforceability or lack of protection of our patents and
proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our
products or technologies obsolete, and other factors. For a further
discussion of these risks, please refer to the risk management
sections in Genmab's most recent financial reports, which are
available on
https://www.globenewswire.com/Tracker?data=4BRtsd1uorOn2vsmDtck_AKIoetjvbcselAPLm8DaC-90uox6r46RmQamJYaQBP6GwRA9pa5oiLHE7DHdJBJ9A==
www.genmab.com and the risk factors included in Genmab's most
recent Annual Report on Form 20-F and other filings with the U.S.
Securities and Exchange Commission (SEC), which are available at
https://www.globenewswire.com/Tracker?data=4BRtsd1uorOn2vsmDtck_Hewisr16aPaSyDzBKBoThFflLNdQNodhb3FXGrYIfZSG5ET9sJq_wEqQrBd5J3mggqBOEK0jd_mXZ10liElzaQ=
www.sec.gov. Genmab does not undertake any obligation to update or
revise forward looking statements in this Company Announcement nor
to confirm such statements to reflect subsequent events or
circumstances after the date made or in relation to actual results,
unless required by law.
Genmab A/S and/or its subsidiaries own the following trademarks:
Genmab(R) ; the Y-shaped Genmab logo(R) ; Genmab in combination
with the Y-shaped Genmab logo(R) ; HuMax(R) ; DuoBody(R) ; DuoBody
in combination with the DuoBody logo(R) ; HexaBody(R) ; HexaBody in
combination with the HexaBody logo(R) ; DuoHexaBody(R) and
HexElect(R) .
Company Announcement no. 11
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122
Genmab A/S
Kalvebod Brygge 43
1560 Copenhagen V
Denmark
Attachment
-- 290322_CA11_Passing of AGM
https://ml-eu.globenewswire.com/Resource/Download/f1ce70fe-0cb2-434f-a63a-9ac7ea7a3669
(END) Dow Jones Newswires
March 29, 2022 09:15 ET (13:15 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Genuit (LSE:GEN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Genuit (LSE:GEN)
Historical Stock Chart
From Mar 2023 to Mar 2024